Mangoceuticals Reports 49% Revenue Decline and Increased Net Loss in Q1 2025

Mangoceuticals, Inc. reported a significant decline in revenue for the first quarter of 2025, generating $109,306 compared to $214,095 in the same period of 2024, marking a decrease of approximately 49%. The company's cost of revenues increased to $24,737 from $20,795 year-over-year, while the cost of revenues from related parties decreased to $22,505 from $45,902. The overall gross profit fell to $62,064, down from $147,398 in the previous year. The net loss for the quarter was $4,839,489, a substantial increase from the $2,367,617 loss reported in the first quarter of 2024.

The company's operating expenses surged to $4,915,253, up from $2,515,015 in the prior year, driven by increased general and administrative costs, which rose to $1,542,444 from $771,958. Notably, investor relations expenses skyrocketed to $1,419,000 from $143,000, reflecting heightened efforts to raise public awareness of the company's stock. Stock-based compensation also increased significantly, totaling $1,045,479 compared to $454,465 in the previous year. The increase in expenses contributed to the larger net loss reported for the quarter.

Strategically, Mangoceuticals has been active in expanding its product offerings and market presence. The company entered into a Master Distribution Agreement with Navy Wharf, Ltd. for the exclusive rights to market a nutraceutical product aimed at managing blood glucose levels, branded as Diabetinol®. Additionally, the company acquired intellectual property related to respiratory illness prevention technology from Smokeless Technology Corp., which will allow it to enter a new market segment. These agreements are expected to enhance the company's product portfolio and revenue potential in the future.

As of March 31, 2025, Mangoceuticals had total assets of $21.8 million, up from $15.4 million at the end of 2024, primarily due to the acquisition of intangible assets. The company reported total liabilities of $1.5 million, resulting in a working capital deficit of approximately $1.36 million. The company continues to rely on funding from related parties and capital raised through the sale of securities to support its operations. Mangoceuticals anticipates needing additional funding to sustain its operations and pursue growth opportunities, which may involve significant dilution for existing shareholders.

Looking ahead, Mangoceuticals plans to continue its focus on marketing and expanding its product offerings while exploring strategic acquisitions. The company is also preparing for a re-launch of its telehealth platform, which it hopes will improve customer engagement and drive revenue growth. However, the company acknowledges the need for additional capital to support its operations and growth strategy, raising concerns about its ability to continue as a going concern if funding is not secured.